The PI3K-AKT-mTOR signaling network in AML
B Beagle, DA Fruman - Targeted Therapy of Acute Myeloid Leukemia, 2015 - Springer
Acute myelogenous leukemia (AML) is the most common leukemia in adults. Currently, AML
patients are treated mainly with combinations of cytotoxic chemotherapies. There is an …
patients are treated mainly with combinations of cytotoxic chemotherapies. There is an …
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells
The proapoptotic death receptor 5 (DR5) expressed by tumor associated endothelial cells
(TECs) mediates vascular disrupting effects of human CD34+ cells engineered to express …
(TECs) mediates vascular disrupting effects of human CD34+ cells engineered to express …
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors
M Schmidt-Hieber, R Dabrowski, B Aicher… - Investigational new …, 2012 - Springer
The novel AKT inhibitor perifosine possesses myelopoiesis-stimulating effects in rodents.
We studied the in vitro effects of the novel agents perifosine, bortezomib and lenalidomide in …
We studied the in vitro effects of the novel agents perifosine, bortezomib and lenalidomide in …
Exploring Newer Agents for Reversal of Adriamycin Resistance in Acute Myeloid Leukemia
RH Alghamdi - 2023 - platform.almanhal.com
Acute myeloid leukemia (AML) is a heterogeneous and clonal disorder of the blood-forming
myeloid cells, characterized by an aberrant proliferation and impaired differentiation …
myeloid cells, characterized by an aberrant proliferation and impaired differentiation …
Development of drugs targeting the pi3k signalling pathway in leukaemias and lymphomas
A Arcaro - European Medical Journal Oncology, 2015 - boris.unibe.ch
The phosphoinositide 3-kinase (PI3K) family of signalling enzymes play a key role in the
transduction of signals from activated cell surface receptors controlling cell growth and …
transduction of signals from activated cell surface receptors controlling cell growth and …
The Par-4 Tumor Suppressor Protein in TCL1-Induced Leukemogenesis
JT Greene, MK McKenna, S Bondada… - Tumor Suppressor Par-4 …, 2021 - Springer
Abstract Prostate apoptosis response 4 (Par-4) is a pleiotropic tumor suppressor protein that
is downregulated in numerous solid tumors to evade its pro-apoptotic and cytostatic effects …
is downregulated in numerous solid tumors to evade its pro-apoptotic and cytostatic effects …
[PDF][PDF] Targeting the phosphatidylinositol 3-kinase signaling pathway in acute myeloid leukemia
O Fuchs - siriusstore.com
Abstract The phosphatidylinositol-3-kinase-Akt (protein kinase B)-mechanistic target of
rapamycin (PI3K-Akt-mTOR) pathway is often dysregulated in cancer, including …
rapamycin (PI3K-Akt-mTOR) pathway is often dysregulated in cancer, including …
Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway
L Wang, Y Chu, T Cheng, W Yuan - Zhonghua xue ye xue za zhi …, 2015 - europepmc.org
[Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway]. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
小分子AKT 抑制剂及其在肺癌治疗中的研究进展
麦琳 - 中华肺部疾病杂志(电子版), 2011 - cqvip.com
小分子AKT抑制剂及其在肺癌治疗中的研究进展-[维普官方网站]-www.cqvip.com-维普网 我的
维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 …
维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 …
Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
J Engel, E Günther, H Sindermann - US Patent 8,389,497, 2013 - Google Patents
The invention relates to the use of alkylphosphocholines in combination with antitumor
medicaments for the treatment of benign and malignant oncoses in humans and animals. It …
medicaments for the treatment of benign and malignant oncoses in humans and animals. It …